ERK Inhibitor Compounds with Halogen Substituents
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current ERK inhibitors face challenges due to poor chemical stability and unsatisfactory pharmacokinetic parameters, leading to difficulties in drug development, particularly under alkaline conditions and in generating impurities, which limits their effectiveness in cancer treatment.
Innovation Solution
Development of novel compounds with a core structure featuring halogen, unsubstituted alkyl, haloalkyl, or deuterated alkyl groups, which exhibit improved chemical stability, solubility, and permeability, demonstrating potent ERK kinase inhibitory activity and favorable pharmacokinetic parameters.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If compounds with structure (I) are used as ERK inhibitors, then ERK kinase inhibitory activity is achieved, but chemical stability deteriorates and impurities are generated under alkaline conditions
Solution Approach 1:
The patent modifies the chemical structure of compounds by changing specific parameters (substituents at positions R3 and R4) to improve chemical stability while maintaining ERK kinase inhibitory activity. This involves systematic variation of molecular structures to achieve optimal balance between activity and stability.
Solution Approach 2:
The patent creates composite molecular structures by combining specific structural motifs (core structure with halogen, alkyl, haloalkyl, or deuterated alkyl groups) to achieve both ERK inhibition and chemical stability. The composite nature of these molecules allows simultaneous optimization of multiple properties.
2Reliability
If compounds with structure (I) are used as ERK inhibitors, then ERK kinase inhibitory activity is achieved, but pharmacokinetic parameters become unsatisfactory
Solution Approach 1:
The patent optimizes pharmacokinetic parameters by systematically changing molecular parameters (substituents at R3 and R4 positions) to improve solubility, permeability, and other PK properties while maintaining target engagement.
Solution Approach 2:
The patent applies local modifications at specific positions (R3 and R4) of the molecular structure to achieve desired pharmacokinetic properties. By locally adjusting specific substituents, the patent optimizes overall drug properties without compromising the core inhibitory mechanism.
3Reliability
If B-Raf and MEK inhibitors are used to treat cancer, then tumor growth is inhibited, but tumors rapidly become resistant through point mutation and protein changes
Solution Approach 1:
The patent positions ERK inhibition as an intermediary target in the MAPK pathway. By blocking the terminal kinase ERK, the patent creates a therapeutic strategy that is less susceptible to upstream resistance mechanisms, effectively mediating against tumor adaptation.
Solution Approach 2:
Instead of targeting upstream nodes (B-Raf, MEK) where resistance develops, the patent inverts the approach by targeting the downstream terminal node (ERK). This inversion of the therapeutic strategy prevents resistance by blocking the final common pathway before adaptation can occur.
Data Source
Figure 1~4
AI summary
The invention relates to a compound of formula (I): wherein variables are as defined in the specification. The compound is an inhibitor of an ERK kinase, e.g. ERK1 and/or ERK2 kinase. The invention also relates to the use of the compound and a method for preparing the compound, and a pharmaceutical composition containing the compound.